Prostate Cancer | Specialty

Dr. Agarwal on Treatment for Newly Diagnosed Prostate Cancer

January 20th 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses treatment options for patients with newly diagnosed prostate cancer.

Genetic Model Predicts Age of Onset for Aggressive Prostate Cancer

January 20th 2018

By combining data from genome-wide association studies with epidemiological surveys, investigators say they have developed a genetic tool that can predict age of onset for aggressive prostate cancer.

Dr. Sweeney on Chemotherapy in Prostate Cancer

January 19th 2018

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses when to give docetaxel as a treatment option for patients with prostate cancer.

Dr. Mason on the Significant Results from the PROTECT Study in Prostate Cancer

January 18th 2018

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significant results of the PROTECT study for patients with prostate cancer.

Abiraterone Associated With Improved PROs in Metastatic Prostate Cancer

January 17th 2018

Men with newly diagnosed mCRPC in the global LATITUDE trial reported clinical improvements in pain progression, prostate cancer symptoms, fatigue, functional decline, and overallHR-QOL following treatment with abiraterone acetate plus prednisone.

Dr. Morgan on the Role of PARP Inhibitors in Prostate Cancer

January 17th 2018

Alicia Morgan, MD, Mather Hospital, discusses the role of PARP inhibitors for patients with prostate cancer.

Dr. Oh Discusses Immunotherapy in Prostate Cancer

January 13th 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the role of immunotherapy for patients with prostate cancer.

Experts Discuss Optimal Timing of New Prostate Cancer Therapies

January 13th 2018

Layering of therapies and advances in next-generation imaging and sequencing are key reasons that outcomes are improving in advanced prostate cancer.

Dr. Agarwal on the Advantages of Docetaxel in Prostate Cancer

January 12th 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the advantages and disadvantages of choosing docetaxel as a therapy for patients with mCRPC.

Metastasis-Directed Therapy Shows Promise in Oligorecurrent Prostate Cancer

January 12th 2018

For patients with oligorecurrent prostate cancer, androgen deprivation therapy–free survival was superior for those assigned to metastasis-directed therapy versus surveillance.

Bipolar Androgen Therapy Effective After Enzalutamide in mCRPC

January 11th 2018

One-third of asymptomatic men with metastatic castration-resistant prostate cancer who progressed on enzalutamide (Xtandi) achieved a 50% decline in PSA concentration from baseline (PSA50) following bipolar androgen therapy.

Dr. Sweeney Discusses Tailoring Treatment in Prostate Cancer

January 11th 2018

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses tailoring treatment to individual patients with prostate cancer.

Fresh Look at Gene Fusion Yields Clues in Low-Risk Prostate Cancer

January 10th 2018

Although gene fusions between the TMPRSS2 gene and ETS family of transcription factors in prostate cancer have been recognized for more than a decade, the clinical relevance of this fusion event continues to be debated among experts.

Dr. Graff Discusses the Treatment of Prostate Cancer

January 9th 2018

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.

Dr. Oh on the Hormone-Sensitive Setting in Prostate Cancer

January 6th 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the hormone-sensitive setting of prostate cancer.

Second-Line Docetaxel Superior to ARATA in mCRPC

December 29th 2017

Men with metastatic castration-resistant prostate cancer who progressed following initial treatment with an androgen receptor-axis-targeted agent had better survival when treated with docetaxel in second-line.

The Future of Treatment for Nonmetastatic CRPC

December 28th 2017

Nonmetastatic CRPC: The Changing Landscape of Treatment

December 28th 2017

Enzalutamide in the Context of Nonmetastatic CRPC

December 28th 2017

Darolutamide's Role in Treating Nonmetastatic CRPC

December 28th 2017